









Markets
/
Stocks
/
nasdaq-bdrx
/

Biodexa Pharmaceuticals PLC

BDRX

5.480USD

+0.240+4.78%

Close 11/14, 16:00（ET）Quotes delayed by 15 min

33.95BMarket Cap

--P/E TTM



Biodexa Pharmaceuticals PLC

5.480

+0.240+4.78%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biodexa Pharmaceuticals PLC

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biodexa Pharmaceuticals PLC's Score

Industry at a Glance

Industry Ranking

303 / 501

Overall Ranking

581 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

180.000

Target Price

+3184.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Biodexa Pharmaceuticals PLC Highlights

StrengthsRisks

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Overvalued

The company’s latest PE is 42.72, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 38.88K shares, increasing 39.59% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 34.78%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Biodexa Pharmaceuticals PLC's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is 42.72, which is 12.80% below the recent high of 48.19 and 152968000.15% above the recent low of -65344827.59.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 303/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Biodexa Pharmaceuticals PLC is 180.00, with a high of 180.00 and a low of 180.00.

Score

Industry at a Glance

Previous score

10.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

180.000

Target Price

+3184.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

523

Total

Median

Average

Company name

Ratings

Analysts

Biodexa Pharmaceuticals PLC

BDRX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

105

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 1.16, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 10.77 and the support level at 5.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.26

Change

-0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.185

Sell

RSI(14)

42.483

Neutral

STOCH(KDJ)(9,3,3)

40.982

Buy

ATR(14)

0.689

Low Volatility

CCI(14)

-63.535

Neutral

Williams %R

78.105

Sell

TRIX(12,20)

-1.316

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.388

Buy

MA10

5.474

Buy

MA20

6.158

Sell

MA50

6.655

Sell

MA100

5.227

Buy

MA200

3.635

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 6.28%, representing a quarter-over-quarter decrease of 16.21%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cavalry Fund I Management, LLC

17.52K

Brio Capital Management LLC

16.77K

+193.61%

UBS Switzerland AG

199.00

-80.37%

Abbe (Richard)

2.43K

Bukwang Pharmaceutical Co., Ltd.

1.42K

Melior Pharmaceuticals I, Inc.

1.42K

Mercer Street Capital Partners, LLC

1.42K

+126.88%

GAMMA Investing LLC

1.35K

+13.23%

GS Capital Partners LLC

631.00

District 2 Capital LP

403.00

-52.70%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.